Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cerus Corp (CERS)
NASDAQ:CERS
Earnings Data
Report Date
May 01, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.04Last Year’s EPS
-0.05Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 20, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 01, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Cerus Corporation's strong financial performance in 2024, marked by positive adjusted EBITDA and robust revenue growth driven by the IFC and global platelet businesses. However, challenges such as a decline in government contract revenue and increased operating expenses were noted. The overall sentiment is positive given the company's growth trajectory and market expansion efforts.Company Guidance
During Cerus Corporation's fourth quarter and full-year 2024 earnings call, the company provided guidance for 2025, detailing several key financial metrics. They anticipate product revenue growth of 8% to 11% year-over-year. The company achieved positive adjusted EBITDA in 2024, a milestone they plan to build on, with expectations to maintain or improve this metric in 2025. Operating expenses are projected to rise modestly due to inflationary pressures, but Cerus aims to leverage these expenses to support revenue growth. The company also expects to continue generating positive operating cash flows in 2025, following $11.4 million in positive cash flow from operations in 2024. Additionally, the company is working on a potential new and enhanced CE Mark submission for INTERCEPT red blood cells in Europe and remains focused on expanding its INTERCEPT platelet and IFC product lines globally.Positive Adjusted EBITDA Achieved
Cerus Corporation successfully achieved positive adjusted EBITDA for the full year 2024, marking a significant milestone in their long history.
Double-Digit Product Revenue Growth
Year-over-year double-digit product revenue growth for 2024 was driven by expansion in the global platelets business and rising demand in the INTERCEPT Fibrinogen Complex (IFC) business in the U.S.
Strong IFC Sales Expansion
IFC sales were up 42% over 2023 levels, totaling $9.2 million for the year, with the fourth quarter showing a 30% increase compared to the prior year.
Global Market Penetration and Expansion
Canadian Blood Services reached 100% pathogen reduction (PR) adoption for platelet production, and significant interest was shown in markets such as China, Brazil, and the Middle East.
---
CERS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CERS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 20, 2025 | $1.74 | $1.65 | -5.17% |
| Oct 30, 2024 | $1.72 | $1.57 | -8.72% |
| Aug 01, 2024 | $2.04 | $2.34 | +14.71% |
| May 02, 2024 | $1.76 | $1.62 | -7.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cerus Corp (CERS) report earnings?
Cerus Corp (CERS) is schdueled to report earning on May 01, 2025, TBA Not Confirmed.
What is Cerus Corp (CERS) earnings time?
Cerus Corp (CERS) earnings time is at May 01, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CERS EPS forecast?
CERS EPS forecast for the fiscal quarter 2025 (Q1) is -0.04.
---